Headquartered in Tavor Building, Yokne'am Fiscal year ends December NASDAQ: INMD inmodemd.com
InMode Ltd. develops, manufactures and markets medical aesthetic and surgical devices based on proprietary radio frequency (RF) technology. Its portfolio spans minimally invasive, hands-free and non-invasive platforms used in plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology.
Revenue comes primarily from capital equipment sales to physicians and clinics. In Q3 2026, capital equipment made up roughly 79% of revenue, split between the United States and international markets. The remainder comes from recurring consumables and service. Minimally invasive technologies accounted for 78% of revenue in the quarter, and products include the Morpheus8 line, recently expanded with Morpheus8 Max.
The company has been investing in its sales organization following a restructuring of its North American sales team. It has seen strong growth in Asia and maintains a substantial cash, deposit and marketable securities position. It has also funded share repurchases.
A Special Committee formed to evaluate unsolicited proposals has completed its work, and the company is resuming investor relations activities. Updated
InMode snapped two straight quarters of missing expectations, beating EPS consensus by 15% and reaffirming full-year revenue guidance of $365 million to $375 million. Gross margin got about a point from a one-time U.S. tariff refund, and non-GAAP operating margin still narrowed to 22% from 25% on the North American sales force rebuild.
InMode Ltd. develops, manufactures and markets medical aesthetic and surgical devices based on proprietary radio frequency (RF) technology. Its portfolio spans minimally invasive, hands-free and non-invasive platforms used in plastic surgery, gynecology, dermatology, otolaryngology and ophthalmology.
The Wall Street consensus 12-month price target for INMD is $15.33.